)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Gufic Biosciences
Gufic Biosciences (509079) investor relations material
Gufic Biosciences Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary16 Feb, 2026
Executive summary
Domestic branded business focuses on protocol-led depth, science-backed differentiation, and execution in hospital injectables, women's health, toxin, and Nutra Ayurveda platforms, with robust R&D and international expansion.
Achieved commercial production at the advanced Indore injectable facility, targeting global regulated markets and reaching 30% utilization in Q3 FY25.
International business advanced with regulatory approvals in Germany, Portugal, Lithuania, Myanmar, and Oman, expanding registrations and direct EU access.
Strong partnerships and licensing deals with global pharma and biotech leaders, including a strategic licensing agreement for fillers and investment in Selvax cancer vaccine therapy.
Standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025, were reviewed and approved by the Board, with no material misstatements found by auditors.
Financial highlights
Q3 FY26 revenue was ₹231.1 Cr, up from ₹207.8 Cr in Q3 FY25; 9M FY26 revenue at ₹688.4 Cr, up from ₹614.8 Cr YoY.
Q3 FY26 EBITDA was ₹37.1 Cr (16.05% margin), down from 17.23% in Q3 FY25; 9M FY26 EBITDA at ₹108.2 Cr.
Q3 FY26 PAT was ₹15.6 Cr (6.75% margin), down from ₹19.3 Cr (9.29%) in Q3 FY25; 9M FY26 PAT at ₹42.6 Cr.
Standalone revenue for the quarter was ₹23,109.36 lakhs, with consolidated revenue at ₹23,220.04 lakhs; standalone net profit was ₹1,556.39 lakhs, consolidated net profit was ₹1,682.40 lakhs.
Historical trend shows declining margins over recent years.
Outlook and guidance
FY27 revenue growth guidance set at a minimum of 15%, with potential upside to 20% if positive factors materialize.
Indore facility expected to be margin accretive by FY27, with global regulatory clearances and US FDA readiness by FY29.
Export revenue from Indore to Europe and regulated markets expected to start in Q3/Q4 FY27, following EU GMP audit completion.
Strategic roadmap targets 5-10% market share in identified geographies over 3-5 years.
The company operates in a single segment: Pharmaceuticals.
Why did Q3 net profit decline YoY despite revenue growth?
Explain the Q3 inventory changes swing
Subsidiary impact on Q3 consolidated net profit
Indore's impact on EBITDA margin trajectory?
Impact of debtor days reduction on cash flow?
Aesthetic portfolio expansion's growth potential?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Gufic Biosciences earnings date
Q4 25/2629 May, 2026
Gufic Biosciences
Next Gufic Biosciences earnings date
Q4 25/2629 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Gufic Biosciences Limited is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and herbal products. The company specializes in injectables, lyophilized formulations, antifungals, antibiotics, and critical care medicines, catering to both domestic and international markets. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage